The reduction in price target by Wedbush is a significant indicator of the firm's adjusted expectation for bluebird bio's stock performance. Given that analyst ratings and price targets can influence market perception and investor sentiment, this adjustment is likely to exert downward pressure on BLUE's stock price in the short term. The Neutral rating suggests that Wedbush does not see significant upside or downside potential from the current price level, but the lowered price target indicates a negative revision of the stock's valuation.